Advances in current treatment for patients with newly diagnosed multiple myeloma

بواسطة Lonial, S
الحاوية / القاعدة Leukemia Suppl (2013)

Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma

بواسطة Lonial, S
الحاوية / القاعدة Leukemia Suppl (2013)

Myeloma therapy pursuing the plasma cell /

بواسطة Lonial, Sagar.
منشور في 2008

Clinical uses of GM-CSF, a critical appraisal and update

بواسطة Arellano, Martha, Lonial, Sagar
منشور في 2008

Association of response endpoints with survival outcomes in multiple myeloma

بواسطة Lonial, S, Anderson, K C
منشور في 2014

Treatment options for patients with relapsed/refractory myeloma who have previously been treated with novel agents and high-dose chemotherapy/autologous stem cell transplant

بواسطة Shah, Nina, Lonial, Sagar
منشور في 2010

Emerging treatments in Castleman disease – a critical appraisal of siltuximab

بواسطة Koff, Jean L, Lonial, Sagar
الحاوية / القاعدة Biologics (2016)

Integration of Novel Agents into the Care of Patients with Multiple Myeloma

بواسطة Orlowski, Robert Z., Lonial, Sagar
الحاوية / القاعدة Clin Cancer Res (2016)

Academic, Foundation, and Industry Collaboration in Finding New Therapies

بواسطة Ramsey, Bonnie W., Nepom, Gerald T., Lonial, Sagar
الحاوية / القاعدة N Engl J Med (2017)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib

بواسطة Nooka, Ajay, Gleason, Charise, Casbourne, Daniela, Lonial, Sagar
منشور في 2013

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

بواسطة Lonial, S, Durie, B, Palumbo, A, San-Miguel, J
الحاوية / القاعدة Leukemia (2016)

When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat Shock Response

بواسطة Shah, Shardule P., Lonial, Sagar, Boise, Lawrence H.
الحاوية / القاعدة Mol Cancer Res (2015)

Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070

بواسطة Dong, S, Kang, S, Lonial, S, Khoury, HJ, Viallet, J, Chen, J
منشور في 2007

TG02 inhibits proteasome inhibitor–induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma

بواسطة Shah, Shardule P., Nooka, Ajay K., Lonial, Sagar, Boise, Lawrence H.
الحاوية / القاعدة Blood Adv (2017)

The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells

بواسطة Zhao, Liqun, Yue, Ping, Lonial, Sagar, Khuri, Fadlo R, Sun, Shi-Yong
منشور في 2011

Early clonality and high-frequency proviral integration into the c-myc locus in AKR leukemias.

بواسطة O'Donnell, P V, Fleissner, E, Lonial, H, Koehne, C F, Reicin, A
منشور في 1985

Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents

بواسطة Shah, Nishi, Nooka, Ajay K., Lonial, Sagar, Khoury, Hannah J., Waller, Edmund, Langston, Amelia
منشور في 2014

The Tao of myeloma

بواسطة Boise, Lawrence H., Kaufman, Jonathan L., Bahlis, Nizar J., Lonial, Sagar, Lee, Kelvin P.
الحاوية / القاعدة Blood (2014)

Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα Degradation

بواسطة Li, Chunyang, Chen, Shuzhen, Yue, Ping, Deng, Xingming, Lonial, Sagar, Khuri, Fadlo R., Sun, Shi-Yong
منشور في 2010

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax

بواسطة Bajpai, R, Matulis, SM, Wei, C, Nooka, AK, Von Hollen, HE, Lonial, S, Boise, LH, Shanmugam, M
الحاوية / القاعدة Oncogene (2015)